QT
PRLD icon

Quantbot Technologies’s Prelude Therapeutics PRLD Stock Holding History

Quantbot Technologies’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-800
Closed -$4.83K – 1961
2022
Q4 		$4.83K Sell
800
-600
-43% -$3.85K ﹤0.01% 1556
2022
Q3 		$9K Sell
1,400
-1,400
-50% -$9.44K ﹤0.01% 1440
2022
Q2 		$14K Buy
+2,800
New +$14.3K ﹤0.01% 1498
2022
Q1 		– Sell
-8,200
Closed -$102K – 1973
2021
Q4 		$102K Buy
8,200
+8,000
+4,000% +$130K 0.01% 870
2021
Q3 		$6K Buy
+200
New +$6.47K ﹤0.01% 1404

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quantbot Technologies's PRLD Position: Q1 2023 in Review

Quantbot Technologies sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 800 shares — an estimated $4.83K sold.

Quantbot Technologies first reported a position in PRLD in Q3 2021 and held it in 5 quarters. The position peaked at $102K in Q4 2021. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

  • Quantbot Technologies reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Quantbot Technologies sold 800 Prelude Therapeutics shares in Q1 2023, an estimated $4.83K.
  • Quantbot Technologies first reported a position in Prelude Therapeutics in Q3 2021 and held it in 5 quarters.
  • Quantbot Technologies's Prelude Therapeutics position peaked at $102K in Q4 2021.
  • 54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on Quantbot Technologies's 13F filing for Q1 2023, filed 12 May 2023.